A detailed history of D. E. Shaw & Co., Inc. transactions in Regeneron Pharmaceuticals, Inc. stock. As of the latest transaction made, D. E. Shaw & Co., Inc. holds 266,236 shares of REGN stock, worth $201 Million. This represents 0.26% of its overall portfolio holdings.

Number of Shares
266,236
Holding current value
$201 Million
% of portfolio
0.26%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$1024.09 - $1201.76 $12.1 Million - $14.2 Million
11,821 Added 4.65%
266,236 $280 Million
Q2 2024

Aug 14, 2024

BUY
$883.2 - $1071.19 $21.1 Million - $25.6 Million
23,944 Added 10.39%
254,415 $267 Million
Q1 2024

May 15, 2024

SELL
$902.69 - $993.35 $121 Million - $133 Million
-133,587 Reduced 36.69%
230,471 $222 Million
Q4 2023

Feb 14, 2024

SELL
$775.18 - $881.7 $4.93 Million - $5.61 Million
-6,363 Reduced 1.72%
364,058 $320 Million
Q3 2023

Nov 14, 2023

BUY
$692.45 - $844.37 $57.2 Million - $69.8 Million
82,642 Added 28.72%
370,421 $305 Million
Q2 2023

Aug 14, 2023

BUY
$700.03 - $830.35 $95.5 Million - $113 Million
136,446 Added 90.16%
287,779 $207 Million
Q1 2023

May 15, 2023

BUY
$680.49 - $826.97 $91.9 Million - $112 Million
135,038 Added 828.71%
151,333 $124 Million
Q4 2022

Feb 14, 2023

SELL
$705.89 - $766.39 $14.9 Million - $16.2 Million
-21,130 Reduced 56.46%
16,295 $11.8 Million
Q3 2022

Nov 14, 2022

SELL
$573.97 - $724.32 $15.4 Million - $19.5 Million
-26,903 Reduced 41.82%
37,425 $25.8 Million
Q2 2022

Aug 15, 2022

SELL
$548.35 - $738.84 $74.2 Million - $100 Million
-135,375 Reduced 67.79%
64,328 $38 Million
Q1 2022

May 16, 2022

SELL
$595.12 - $698.43 $55.4 Million - $65.1 Million
-93,168 Reduced 31.81%
199,703 $139 Million
Q4 2021

Feb 14, 2022

BUY
$543.48 - $670.97 $65.6 Million - $81 Million
120,736 Added 70.14%
292,871 $185 Million
Q3 2021

Nov 15, 2021

BUY
$574.03 - $680.96 $68.4 Million - $81.1 Million
119,119 Added 224.69%
172,135 $104 Million
Q2 2021

Aug 16, 2021

BUY
$472.8 - $558.54 $15.3 Million - $18 Million
32,316 Added 156.12%
53,016 $29.6 Million
Q1 2021

May 17, 2021

SELL
$446.73 - $548.2 $15.6 Million - $19.2 Million
-34,958 Reduced 62.81%
20,700 $9.79 Million
Q4 2020

Feb 16, 2021

BUY
$478.3 - $607.98 $3.58 Million - $4.56 Million
7,495 Added 15.56%
55,658 $26.9 Million
Q3 2020

Nov 16, 2020

BUY
$544.75 - $658.21 $7.66 Million - $9.25 Million
14,060 Added 41.23%
48,163 $27 Million
Q2 2020

Aug 14, 2020

SELL
$493.32 - $643.92 $2.21 Million - $2.89 Million
-4,485 Reduced 11.62%
34,103 $21.3 Million
Q1 2020

May 15, 2020

SELL
$336.18 - $494.43 $14.1 Million - $20.7 Million
-41,893 Reduced 52.05%
38,588 $18.8 Million
Q4 2019

Feb 14, 2020

SELL
$274.13 - $376.51 $15.4 Million - $21.2 Million
-56,341 Reduced 41.18%
80,481 $30.2 Million
Q3 2019

Nov 14, 2019

SELL
$273.46 - $318.39 $31.2 Million - $36.4 Million
-114,237 Reduced 45.5%
136,822 $38 Million
Q2 2019

Aug 14, 2019

BUY
$299.6 - $414.82 $18.8 Million - $26 Million
62,639 Added 33.24%
251,059 $78.6 Million
Q1 2019

May 15, 2019

SELL
$372.08 - $439.57 $63.3 Million - $74.8 Million
-170,246 Reduced 47.47%
188,420 $77.4 Million
Q4 2018

Feb 14, 2019

BUY
$335.82 - $403.04 $52.7 Million - $63.3 Million
156,989 Added 77.84%
358,666 $134 Million
Q3 2018

Nov 14, 2018

SELL
$351.14 - $408.51 $43.2 Million - $50.2 Million
-122,963 Reduced 37.88%
201,677 $81.5 Million
Q2 2018

Aug 14, 2018

SELL
$284.6 - $344.99 $94.8 Million - $115 Million
-333,070 Reduced 50.64%
324,640 $112 Million
Q1 2018

May 15, 2018

BUY
$315.82 - $393.78 $38.5 Million - $48 Million
122,000 Added 22.77%
657,710 $226 Million
Q4 2017

Feb 14, 2018

BUY
$358.63 - $469.95 $160 Million - $210 Million
446,025 Added 497.32%
535,710 $201 Million
Q3 2017

Nov 14, 2017

BUY
$431.38 - $504.0 $38.7 Million - $45.2 Million
89,685
89,685 $40.1 Million

Others Institutions Holding REGN

About REGENERON PHARMACEUTICALS, INC.


  • Ticker REGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 107,190,000
  • Market Cap $81.1B
  • Description
  • Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...
More about REGN
Track This Portfolio

Track D. E. Shaw & Co., Inc. Portfolio

Follow D. E. Shaw & Co., Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of D. E. Shaw & Co., Inc., based on Form 13F filings with the SEC.

News

Stay updated on D. E. Shaw & Co., Inc. with notifications on news.